Stock comparison
Merck &
ResMed
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
MRK
Merck &
Market cap
$302.33B
Sector
Healthcare
RMD
ResMed
Market cap
$30.18B
Sector
Healthcare
Overall winner
ResMed RMD
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | MRK | RMD | Winner |
|---|---|---|---|
| Warren Buffett | 64C | 72B | RMD |
| Benjamin Graham | 78B | 75B | MRK |
| Philip Fisher |
Side-by-side metrics
| Metric | MRK | RMD |
|---|---|---|
| Market cap | $302.33B | $30.18B |
| P/E (TTM) | 31.5x | 19.6x |
| EV/EBIT | 13.9x | 17.1x |
| ROIC (TTM) | 13.34% | 19.63% |
| Gross margin | 75.91% | 61.69% |
| Net margin | 13.62% | 27.44% |
| Revenue CAGR 5y | 7.45% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
MRK leads on
- Market cap$302.33Bvs $30.18B+90%
- Dividend yield2.91%vs 1.14%+61%
- EV/EBIT13.9xvs 17.1x+19%
- Gross margin75.91%vs 61.69%
More like RMD
Related on invest-like
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.